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Abstract
Purpose Our purpose was to investigate the feasibility
of pharmacy-initiated pharmacogenetic (PGt) screening
in primary care with respect to patient willingness to
participate, quality of DNA collection with saliva kits,
genotyping, and dispensing data retrieved from the
pharmacy.
Methods Polypharmacy patients aged >60 years who
used at least one drug with Anatomical Therapeutic
Chemical (ATC) code N06AA01–N06AX19 (antidepres-
sants), A02BC01–A02BC05 (proton-pump inhibitors),
N05AA01–N05AH04 (antipsychotics), or C07AB02
(metoprolol) in the preceding 2 years were randomly
selected. DNA was collected with saliva kits and
genotyped for CYP2D6 and CYP2C19 with the AmpliChip.
Pharmacy dispensing records were retrieved and screened for
drugs interacting with the patient’s CYP2D6 and CYP2C19
genotype by using the evidence-based PGt guidelines from
the Dutch Pharmacogenetics Working Group.
Results Out of the 93 invited patients, 54 (58.1%) provided
informed consent. Nine saliva samples (16.7%) contained
too little DNA. Call rates for CYP2D6 and CYP2C19 were
93.3% and 100%, respectively. Frequencies of genotype-
predicted phenotype were 2.4%, 38.1%, 54.8%, and 4.8%
for CYP2D6 poor metabolizers (PM), intermediate metab-
olizers (IM), extensive metabolizers (EM), and ultrarapid
metabolizers (UM) respectively. For CYP2C19 genotype-
predicted phenotype, frequencies were 2.2%, 15.6%, and
82.2% for PM, IM, and EM, respectively.
Conclusions This study shows that pharmacy-initiated PGt
screening is feasible for a primary care setting.
Keywords Pharmacogenetics.Cytochrome P-450
CYP2D6.Cytochrome P-450 CYP2C19.
Primary health care
Introduction
Pharmacogenetics (PGt) promises an exciting approach to a
more individualized drug therapy, ultimately leading to a
more efficient and safer application of drugs. To date, many
efforts within the field of PGt have been aimed at
improving drug therapy with high-risk medications, such
as those used within the field of oncology. By contrast,
multiple PGt interventions for drug therapies with lower
risk might also prove beneficial [1]. Yet the clinical use of
genotyping prior to drug prescribing and dispensing is not
widely practiced. [2] PGt information is accumulating
rapidly, and it was reported that based on the available
PGt information, it is possible to generate advice for nearly
100 drugs for patients with a completely sequenced
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DOI 10.1007/s00228-011-1130-4genome. [3] In addition, Philips et al. reported that 16 of
27 (59%) drugs most commonly associated with adverse
drug reactions (ADRs) were metabolized by a poly-
morphic gene. [4] A subsequent study published by Grice
et al. investigated the frequency of use of these 16 PGt
ADR-associated drugs in a primary care setting. [5]I tw a s
reported that 28.6% of patients took more than one PGt
ADR-associated drug, indicating a high potential for
PGt to make drug therapy safer. A disadvantage of that
study was that it did not include drugs for which PGt
testing is recommended to enhance efficacy instead of
to avoid ADRs. Van Puijenbroek et al. reported their
study aimed at gaining insight into the feasibility of
informing physicians reporting ADRs to The Netherlands
Pharmacovigilance Centre about possible PGt involvement
and genotyping their patients. The authors reported that
39.5% of the reporting health-care professionals actually
initiated genotyping. [6] This illustrates that incorporating
PGt information in drug prescribing could increase safety
of drug therapy.
Two large (inter)national initiatives aimed at providing
PGt-based guidelines and recommendations concerning
drug prescribing have been published. [7, 8] The Clinical
Pharmacogenetics Implementation Consortium (CPIC)
published its first guideline [9], with the goal of
providing peer-reviewed, evidence-based, freely accessible
guidelines for gene/drug pairs. CPIC published a list of 29
gene/drug pairs that were ranked highest in a survey of
the American Society for Clinical Pharmacology and
Therapeutics members in 2010. [7]T h eD u t c hP h a r m a -
cogenetics Working group published updated evidence-
based guidelines with PGt recommendations concerning
53 drugs. [8] From that group’sl i s to fh i g h e s t - r a n k e d
priority gene/drug pairs from CPIC and the article by
Grice et al. [5], it can be observed that many drugs used in
primary care are to some extent influenced by PGt, again
illustrating a potential role for PGt in primary care.
The aim of our study was to test the feasibility of
pharmacy-initiated PGt screening in primary care with
respect to patient willingness to participate, quality of DNA
collection with saliva kits, genotyping, and quality of
dispensing data retrieved from pharmacy records.
Methods
Study setting
In The Netherlands, the vast majority of the population
obtains their medication from only one community
pharmacy, enabling collection of complete medication
histories. [10] The pharmacy keeps an electronic patient
record that covers all dispensing data. Polypharmacy
patients were recruited from a community pharmacy
located in the city of Leiden, The Netherlands. Patients
were selected from the pharmacy records if they used at
least one drug that is metabolized by CYP2D6 or
CYP2C19 and at least four additional drugs in the
preceding 2 years. Drugs were selected on their Anatomical
Therapeutic Chemical (ATC) classification code [http://
www.whocc.no/atc_ddd_index/]. To identify eligible ATC
codes, we used textbooks, an academic Web site [http://
medicine.iupui.edu/flockhart/table.htm], and a review article
by Kirchheiner et al. [11–13]. Codes eligible for inclusion
comprised N06AA01–N06AX19 (antidepressants), A02BC01–
A02BC05 (proton-pump inhibitors), N05AA01–N05AH04
(antipsychotics), and ATC-code C07AB02 (metoprolol).
P a t i e n t sh a dt ob e≥60 years at the start of the study.
This age was chosen for the practical reason that elderly
patients are more frequently at home, thus simplifying
saliva collection.
Sample collection
Samples of 2 ml saliva were collected during a 30-min
house visit. Samples were collected in the Oragene DNA
self-collection kit (DNA Genotek Inc Ottawa, Ontario,
Canada). A sample of 125 patients was drawn from the
selected patients by randomization, with the aim of inviting
100 patients by mail and to finally obtain DNA samples
from 50 patients. General practitioners were informed of
our study prior to contacting the patient and asked to
exclude patients with terminal disease status. Patients
selected for inclusion received a letter from the pharmacy
explaining the study background and objectives. Approxi-
mately 1–2 weeks after the letter was sent, patients were
contacted by phone by one of the pharmacists participating
in the study (EV). During this phone call, patients were
asked if they agreed to participate. If so, a 30-min house
visit was planned to collect informed consent and a saliva
specimen. If the first attempt to contact a patient by phone
was unsuccessful, a maximum of three consecutive
attempts was made. After that, the patient was considered
not willing to participate. The study was approved by the
ethics committee of the Leiden University Medical Center.
Informed consent was obtained from all participants.
Genotyping
DNA was extracted from saliva using the Oragene DNA
self-collection kit according to the manufacturer’s instruc-
tion at the Leiden University Medical Center (Leiden, The
Netherlands). DNA concentrations were measured with
nanodrop (Isogen, Maarssen, The Netherlands) and diluted
with water to a concentration of 10 ng/μl. The DNA was
tested for 29 known polymorphisms in the CYP2D6 gene,
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major polymorphisms in the CYP2C19 gene. Genotyping
was performed at the Department of Clinical Chemistry of
the Erasmus MC (Rotterdam, The Netherlands) using the
AmpliChip CYP450 test (Roche Molecular Systems,
Alameda, CA, USA) according to the manufacturer’s
instruction. A genotype-predicted-phenotype (phenotype)
was assigned to each patient. [8] For CYP2D6, intermediate
metabolizers (IMs) were defined as patients carrying two
decreased-activity (*9, *10, *17, *29, *36, *41) alleles or
carrying one active (*1, *2, *33, *35) and one inactive (*3–
*8, *11–*16, *19–*21, *38, *40, *42) allele, or carrying
one decreased-activity (*9, *10, *17, *29, *36, *41) allele
and one inactive (*3–*8, *11–*16, *19–*21, *38, *40, *42)
allele. Poor metabolizers (PMs) were defined as patients
carrying two inactive (*3–*8, *11–*16, *19–*21, *38, *40,
*42) alleles. Ultrarapid metabolizers (UMs) were defined as
patients carrying a gene duplication in the absence of
inactive (*3–*8, *11–*16, *19–*21, *38, *40, *42)o r
decreased-activity (*9, *10, *17, *29, *36, *41) alleles. All
other patients were considered extensive metabolizers
(EMs). For CYP2C19, IMs were defined as patients with
one active (*1) and one inactive (*2, *3) allele. PMs were
defined as patients carrying two inactive alleles.
Medication analyses
Data were extracted from the pharmacy dispensing records;
drugs for topical application were excluded. The number of
unique prescribed drugs per patient was calculated as the
number of unique ATC codes prescribed to each patient in
the studied period of 2 years. For each unique prescribed
drug, we checked whether a recommendation was
available in the guidelines of the Dutch Pharmacogenetics
Working Group of the Royal Dutch Association for the
Advancement of Pharmacy. [8] These evidence-based
guidelines contain a comprehensive evaluation of PGt
gene–drug interaction involving 53 drugs and 11 genes.
To illustrate the potential impact of PGt on primary care,
the percentage of prescribed drugs with any PGt recom-
mendation was calculated for each patient and in detail for
PGt recommendations regarding CYP2D6 and CYP2C19.
To evaluate whether patients with a non-EM CYP2D6 or
CYP2C19 status had been empirically switched to non-
CYP2D6 / CYP2C19 substrates, the percentage of
CYP2D6/CYP2C19 substrates with a PGt recommendation
of the total number of prescribed drugs was compared
between EMs and non-EMs.
Statistical analysis
Student's t test was used to evaluate differences in the
percentage of prescribed CYP2D6 and CYP2C19 sub-
strates, and the number of drugs with a recommendation in
the guideline of the Dutch Pharmacogenetics Working
Group between EMs and non-EMs. A p value<0.05 was
regarded as significant. Statistical analysis was conducted
with the SPSS statistical package (version 17.0, SPSS,
Chicago, IL, USA).
Results
Patient response
Five hundred and seven patients representing approximate-
ly 5% of the total registered patient population were
prescribed at least one drug from the selected ATC codes
and at least four additional drugs (Fig. 1). Of these patients,
a random sample of 125 was selected: 22 patients were
excluded because they visited a general practitioner that did
not participate in the study; a further ten patients were
excluded because of terminal disease status as judged by
their general practitioner. Of the 93 invited patients, 54
(58.1%) provided informed consent. Twenty-two (23.7%)
of the 93 invited patients refused to participate, and 17
(18.3%) could not be included for other reasons (Fig. 1).
The mean age of included patients was 71 (range 60–
91) years. Ethnicity was not routinely recorded, but all
patients were of European ancestry as observed during
saliva-sample collection (by EV). There were more women
(61.1%) than men (38.9%) in the cohort. The percentage of
invited men and women who agreed to participate was
54.1% and 65.6%, respectively (p=0.29).
Genotyping
Nine saliva samples contained too little DNA for genotyp-
ing with the AmpliChip (< 50 ng). The call rate after a
single run was 93.3% for CYP2D6 (three no-calls) and
100% for CYP2C19. As expected, the most frequent alleles
were the CYP2D6*1 and CYP2D6*2, with a frequency of
0.35 and 0.21, respectively. The other functional allele, *35,
had a prevalence of 0.10. The CYP2D6*4 allele was the
most frequent zero-activity allele, followed by the *5 and
*3 allele (0.17, 0.02, 0.01, respectively). The inactive
alleles *41, *9, and *10 had a prevalence of 0.06, 0.04, and
0.02, respectively. Most patients (54.8%) were predicted to
have the EM phenotype, followed by IM (38.1%), UM
(4.8%), and PM (2.4%). Prevalence of the CYP2C19* 1 and
*2 alleles was 0.90 and 0.10, respectively. No carriers of
CYP2C19*3 allele were found. One patient was homozy-
gous for the CYP2C19*2 allele and therefore categorized as
PM. Seven patients were heterozygous carriers of the
CYP2C19*2 allele and therefore categorized as IM. All
other patients were considered EMs.
Eur J Clin Pharmacol (2012) 68:363–370 365Medication history
The mean number of unique prescribed drugs per patient
was 15.2 [95% confidence interval (CI) 13.4–17.1] in the 2-
year study period, with an average of 4.6 (95% CI 4.0–5.2)
prescriptions per unique prescribed drug. The percentage of
CYP2D6 substrates with a PGt recommendation of the total
number of prescribed drugs was not different between
CYP2D6 non-EMs, and patients with a predicted CYP2D6
EM phenotype, with 4.70% and 4.86%, respectively (p=
0.95). For CYP2C19, similar results were found, with
8.53% and 9.26% of the prescribed drugs having a PGt
recommendation for non-EMs and EMs, respectively (p=
0.74). For patients with a predicted CYP2D6 or CYP2C19,
non-EM phenotype detailed information about prescriptions
f o rd r u g sf o rw h i c haC Y P 2 D 6o rC Y P 2 C 1 9P G t
recommendation was available are provided in Table 1.
The CYP2D6 PM used no drugs with a CYP2D6 PGt
recommendation. Of the CYP2D6 UMs, one patient used
no drugs with a CYP2D6 PGt recommendation, and one
patient used codeine 10 mg three times daily and paroxetine
20 mg once daily. The codeine was limited to a single
prescription only. The latter patient was also predicted to be
a CYP2C19 IM and used clopidogrel 75 mg once daily and
omeprazole 40 mg twice daily. The reduced metabolic
capacity for CYP2C19 and the drug–drug interaction
between clopidogrel and omeprazole both lead to reduced
formation of the active metabolite of clopidogrel and
subsequent increased risk for therapeutic failure [14, 15].
The CYP2D6 IMs were often prescribed tramadol or
codeine, drugs that both are expected to have a reduced
analgesic effect in CYP2D6 IMs. Metoprolol was also often
prescribed, but according to the guidelines of the Dutch
Pharmacogenetics Working Group only requires a dose
adjustment when used for heart failure. The CYP2C19 IMs
and PM were mostly prescribed proton-pump inhibitors,
which do not require a dose adjustment, as decreased
metabolism results in increased therapeutic efficacy.
As we were interested in the potential impact of PGt
on primary care, the medication history of all patients
was further evaluated for drugs metabolized by enzymes
other than CYP2D6 and CYP2C19. On average patients
used 2.3 (15.9%, 95% CI 1.9–2.7) drugs for which a
recommendation of the Dutch Pharmacogenetics Work-
ing Group was available. The most frequently pre-
scribed drugs with a PGt recommendation were the
proton-pump inhibitors, followed by phenprocoumon
and metoprolol (Table 2). The number of drugs with a
therapeutic recommendation did not differ between EM and
non-EMs, with 2.2 versus 2.5 drugs for CYP2D6 EMs and
non-EMs,respectively(p=0.48), and 2.5 versus 1.8 drugs for
CYP2C19 EMs and non-EMs ,respectively (p=0.24).
Discussion
The available evidence of genetic variants with clinical
relevance regarding both efficacy and toxicity of drug
therapy is accumulating rapidly. Elaborating on this
information, multiple initiatives to develop clear-cut
therapeutic guidelines translating available evidence to
therapeutic recommendations have been initiated [7, 8,
16]. However, there is little information regarding the
potential impact of these recommendations in primary
Fig. 1 Study population
366 Eur J Clin Pharmacol (2012) 68:363–370Table 1 Patients with nonextensive metabolism for CYP2D6 or CYP2C19 and prescribed drugs with a CYP2D6 or CYP2C19 pharmacogenetic
recommendation in the Dutch Pharmacogenetics Working Group guidelines [8]
Subject CYP2D6
phenotype
No. of CYP2D6 drugs
with recommendation
(% total drugs)
Prescribed CYP2D6
drugs with
recommendation
CYP2C19
phenotype
No. of CYP2C19 drugs
with recommendation
(% total drugs)
Prescribed
CYP2C19
drugs with
recommendation
Total no. of
prescribed
different drugs
601 IM 3 (15.0) Metoprolol 200 g
retard qd Tramadol
100 mg/ml drops
EM 2 (10.0) 20
2798 IM 1 (5.6) Tramadol 50 mg qd EM 2 (11.1) 18
11375 IM 0 (0.0) EM 1 (12.5) 8
11793 IM 1 (7.1) Metoprolol 100 mg
retard qd
EM 1 (7.1) 14
15750 IM 1 (4.8) Codeine 20 mg tid EM 1 (4.8) 21
17777 IM 0 (0.0) EM 1 (12.5) 8
27160 IM 0 (0.0) EM 1 (6.7) 15
30182 IM 1 (11.1) Metoprolol 100 mg
retard qd
EM 1 (11.1) 9
30310 IM 0 (0.0) EM 2 (13.3) 15
30430 IM 0 (0.0) PM 1 (4.3) Pantoprazole
40 mg bid
23
123890 IM 0 (0.0) EM 1 (5.9) 17
125010 IM 2 (6.7) Tramadol 50 mg bid
Amitriptyline
10 mg bid
EM 0 (0.0) 30
125073 IM 0 (0.0) EM 1 (4.30 23
138981 IM 0 (0.0) IM 2 (7.7) Pantoprazole
40 mg qd
Omeprazole
40 mg qd
26
143823 IM 2 (6.7) Paroxetine 20 mg qd EM 2 (6.7) 30
Tramadol 50 mg tid
294439 IM 2 (18.2) Codeine 10 mg qid EM 1 (9.1) 11
Metoprolol 50 mg
retard qd
158869 PM 0 (0.0) EM 1 (5.3) 19
272 UM 0 (0.0) EM 1 (4.8) 21
10639 UM 2 (14.3) Codeine 10 mg tid
Paroxetine
IM 2 (14.3) Clopidogrel
75 mg qd
14
20 mg qd Omeprazole
40 mg bid
600 EM 0 (0.0) IM 1 (7.7) Omeprazole
20 mg qd
13
2872 EM 0 (0.0) IM 1 (4.8) Pantoprazole
20 mg qd
21
4634 EM 0 (0.0) IM 1 (10.0) Omeprazole
20 mg qd
10
122600 EM 0 (0.0) IM 1 (11.1) Esomeprazole
40 mg qd
9
214384 EM 1 (8.3) IM 1 (8.3) Omeprazole
20 mg qd
12
Nonextensive phenotypes are indicated in bold. Empty cells indicate that the patient had no prescription for any drug substrate with a
recommendation in the Dutch Pharmacogenetics Working Group guidelines
PM poor metabolizer, IM intermediate metabolizer, EM extensive metabolizer, UM ultrarapid metabolizer, qid four times a day, tid three times a
day, bid two times a day, qd once daily
Eur J Clin Pharmacol (2012) 68:363–370 367care. This study indicates that a majority of patients is
willing to participate in a PGt screening study and that
pharmacy-initiated PGt screening is feasible in a primary
care setting. Of the invited patients, 58.1% was willing to
participate in our study. This is a relatively large
percentage given the fact that screening was not directly
related to a clinical problem. For patients presenting
with an ADR or lack of therapeutic effect, willingness
to participate in PGt screening may be even higher. Age
has also been reported to be of influence on the attitude
toward PGt testing, with younger patients being more
likely to be optimistic about the usefulness of PGt
testing. [17] Therefore, willingness to participate may be
higher in a population younger than 60 years. On the other
hand, we collected DNA samples during a visit at the
patients’ homes. Collection by mail may result in lower
response rates.
More women than men participated in our study,
although there was no statistically significant difference in
the willingness to participate between the sexes. Sex
differences concerning PGt testing have been reported,
with female patients being more likely to have concerns
regarding the possible negative consequences of PGt testing
and being less willing to participate than male patients. [17,
18] However, the finding that more women participated in
this study might simply be explained by the fact that from
65 years onward, the female to male ratio is starting to
increase due to higher life expectancy of women.
The reported allele, genotype, and phenotype fre-
quencies are comparable with previously reported results
obtained with the AmpliChip [19] or other methods, such
as polymerase chain reaction restriction fragment length
polymorphism (PCR- RFLP) in comparable populations of
mainly white individuals. [20, 21]. These results indicate
that no selection bias occurred and that our patient cohort
is representative.
Our study is limited in that we used a dichotomous
outcome parameter to categorize drugs as either being
with or without a PGt recommendation in the Dutch
Pharmacogenetics Working Group guidelines. All drugs
for which, according to the guidelines, a gene–drug
i n t e r a c t i o ni sp r e s e n ta n da na c t i o ni sr e q u i r e dw e r ep u t
in a single category. This is an oversimplification
because the guidelines provide many different types of
recommendations, e.g., advice to adjust the dose, be
extra alert to diminished therapeutic efficacy, or
increased risk for an ADR. Also, the recommendation
depends on the metabolism of the drug, e.g., does the
drug have active metabolites or is it a prodrug? For
example, codeine is used for both pain and cough. The
analgesic effect requires the formation of morphine by
CYP2D6. Therefore, CYP2D6 UMs will require a dose
reduction for an equal pain reduction compared with
EMs, whereas no dose reduction is required for the
effect on cough. Dose adjustments were not investigated
in this feasibility study. In addition, patients who used
at least one drug metabolized by CYP2D6 or CYP2C19
were selected for inclusion. As a result, this study does
not provide quantitative estimates of the incidence of
the use of drugs with a PGt recommendation for
CYP2D6 or CYP2C19 in the Dutch PGt guidelines.
The study was not designed to—and therefore does not—
provide direct evidence that the use of PGt recommendations
results in improved efficacy or decreased toxicity. That
requires further study.
We identified some potential pitfalls for PGt screen-
ing in primary care as performed in this study. First, for
a number of patients, production of the required 2 ml
saliva was difficult. As the included patients used at
least five different medications each, this might be
explained by the use of anticholinergic medication or
other drugs that cause a dry mouth. Indeed, five of the
nine patients who failed to provide sufficient DNA used
this type of medication. Secondly, the no-call rate for
the AmpliChip was 6.7% for CYP2D6. This is relatively
high when compared with results reported by other
groups. In a study with 158 breast cancer patients
treated with tamoxifen, Borges et al. reported a no-call
rate of 0.7%. Serrano et al. reported a no-call rate of 1.6% in
182 Italian breast cancer patients treated with tamoxifen.
Both studies used DNA extracted from whole blood for
Table 2 Frequency of patients with a prescription for a drug with a
recommendation in the Dutch Pharmacogenetics Working Group
guidelines [8]
ATC Drug Patients (n)
A02BC01 Omeprazole 37
A02BC02 Pantoprazole 19
B01AA04 Phenprocoumon 14
C07AB02 Metoprolol 12
N02AX02 Tramadol 7
N06AB05 Paroxetine 5
N06AA09 Amitriptyline 5
R05DA04 Codeine 5
B01AC04 Clopidogrel 4
G03CA03 Estrogen 4
B01AA07 Acenocoumarol 2
N06AB06 Sertraline 2
N02AA05 Oxycodone 1
N06AA10 Nortriptyline 1
N06AA02 Imipramine 1
N06AB04 Citalopram 1
A02BC05 Esomeprazole 1
L04AX01 Azathioprine 1
368 Eur J Clin Pharmacol (2012) 68:363–370genotyping. However, in a large study of 4,532 psychiatric
patients, the no-call rate for CYP2D6 with the Ampli-
Chip was 6.0% after three rounds of testing. [22]I nt h a t
study, it was first attempted to genotype patients with
DNA extracted from buccal swabs or saliva specimens.
When saliva/buccal DNA failed to provide a genotype,
blood DNA was tested. The no-call rate after primary
g e n o t y p i n gw a sa sh i g ha s1 3 % .A c c o r d i n gt ot h e
authors, this was mainly the result of DNA collection
with buccal swabs, as this DNA tends to be contami-
nated by bacterial DNA. [22] DNA extracted from saliva
h a sb e e nr e p o r t e dt ob eo fh i g hq u a l i t ya n das u i t a b l e
alternative to blood DNA. [23] In our laboratory, we
compared genotyping results of an additional set of 24
DNA samples for which both blood and saliva were
available. The no-call rate for saliva was 4% higher
compared with the no-call rate for blood samples, with 3/
24 and 2/24 for saliva vs. blood, respectively. Although
these results are inconclusive and further investigation is
required, they may indicate that DNA extracted from
saliva results in slightly less successful genotyping with
the AmpliChip.
According to the guidelines of the Dutch Pharmaco-
genetics Working Group, approximately 5–10% of drugs
prescribed to patients with aberrant CYP2D6 or
CYP2C19 metabolism require action, such as dose
adjustment or extra awareness for an ADR. [8]I no u r
study, there was no difference in the percentage of
prescribed CYP2D6 and CYP2C19 substrates between
EMs and non-EMs of CYP2D6 or CYP2C19. This
suggests that physicians have not empirically identified
patients with aberrant metabolism, e.g., by switching
patients with side effects to medications that were not
substrate for CYP2D6 or CYP2C19. From Table 1 it can
also be observed that patients with a non-EM phenotype
were prescribed regular drug dosages. Available data do
not allow an in-depth analysis of switching behavior, as
this requires a complete medication history, including the
fist prescription, and not just a cross-sectional period of
2y e a r s .
Of the total number of prescribed medications, 15.9%
had a PGt therapeutic recommendation in the Dutch
guidelines. This number is comparable with a previously
published estimate that 15–20% of prescribed drugs are
metabolized by genetically polymorphic enzymes [24].
However, our results should be interpreted with extreme
caution, as one of the inclusion criteria was the use of at
l e a s to n ed r u gm e t a b o l i z e db yC Y P 2 D 6o rC Y P 2 C 1 9 .
Therefore, the number of drugs with a PGt recommenda-
tion may be overestimated in our data.
In conclusion, this study shows that pharmacy-
initiated PGt screening is feasible for a primary care
setting.
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